Advanced

Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H)

Rosilio, M; Blum, WF; Edwards, DJ; Shavrikova, EP; Valle, D; Lamberts, SWJ; Erfurth, Eva Marie LU ; Webb, SM; Ross, RJ and Chihara, K, et al. (2004) In Journal of Clinical Endocrinology and Metabolism 89(4). p.1684-1693
Abstract
Questions on Life Satisfaction-Hypopituitarism (QLS-H) is a new quality-of-life (QoL) questionnaire developed for adults with hypopituitarism. To determine the effects of long-term GH treatment on QoL, we evaluated QLS-H Z-scores in 576 adult patients with GH deficiency (GHD) enrolled in HypoCCS, an international observational study, using data from five countries in which comparative QLS-H data from the general population were available. Baseline QLS-H Z-scores were significantly lower in GH-deficient patients than in the general population of the same age, gender, and nationality. Z-scores were also significantly lower in female patients vs. males (P=0.006) and in adult-onset vs. childhood-onset GHD (P=0.002). Multivariate analysis... (More)
Questions on Life Satisfaction-Hypopituitarism (QLS-H) is a new quality-of-life (QoL) questionnaire developed for adults with hypopituitarism. To determine the effects of long-term GH treatment on QoL, we evaluated QLS-H Z-scores in 576 adult patients with GH deficiency (GHD) enrolled in HypoCCS, an international observational study, using data from five countries in which comparative QLS-H data from the general population were available. Baseline QLS-H Z-scores were significantly lower in GH-deficient patients than in the general population of the same age, gender, and nationality. Z-scores were also significantly lower in female patients vs. males (P=0.006) and in adult-onset vs. childhood-onset GHD (P=0.002). Multivariate analysis associated female gender, multiple pituitary hormone deficiencies, low serum IGF-I values (<75 μg/liter), and concomitant antidepressant medication with low baseline Z-scores. QLS-H Z-scores increased from -1.02&PLUSMN;1.43 (SD) at baseline to -0.25&PLUSMN;1.34 (SD) after 1 yr of GH treatment (P<0.001) and were no longer significantly different from the general population after 4 yr of treatment. There was no correlation between change in Z-score and GH dose or changes in IGF-I and IGF binding protein-3 during treatment. This study demonstrates that 1) improvements in QoL, as measured by the QLS-H, are maintained during long-term GH replacement therapy of adults with GHD, and 2) the QLS-H is a useful tool for evaluating QoL in hypopituitary patients treated in clinical practice. The authors suggest that evaluation of QoL should be a part of the routine clinical management of adult GH-deficient patients, complementing the measurement of surrogate biological markers or other clinical end points. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Clinical Endocrinology and Metabolism
volume
89
issue
4
pages
1684 - 1693
publisher
The Endocrine Society
external identifiers
  • wos:000220714500027
  • pmid:15070931
  • scopus:11144355352
ISSN
1945-7197
DOI
10.1210/jc.2003-030134
language
English
LU publication?
yes
id
b212f75d-c8e9-4e81-861b-346126ad52bb (old id 281852)
date added to LUP
2007-10-31 09:48:31
date last changed
2017-10-01 04:39:26
@article{b212f75d-c8e9-4e81-861b-346126ad52bb,
  abstract     = {Questions on Life Satisfaction-Hypopituitarism (QLS-H) is a new quality-of-life (QoL) questionnaire developed for adults with hypopituitarism. To determine the effects of long-term GH treatment on QoL, we evaluated QLS-H Z-scores in 576 adult patients with GH deficiency (GHD) enrolled in HypoCCS, an international observational study, using data from five countries in which comparative QLS-H data from the general population were available. Baseline QLS-H Z-scores were significantly lower in GH-deficient patients than in the general population of the same age, gender, and nationality. Z-scores were also significantly lower in female patients vs. males (P=0.006) and in adult-onset vs. childhood-onset GHD (P=0.002). Multivariate analysis associated female gender, multiple pituitary hormone deficiencies, low serum IGF-I values (&lt;75 μg/liter), and concomitant antidepressant medication with low baseline Z-scores. QLS-H Z-scores increased from -1.02&amp;PLUSMN;1.43 (SD) at baseline to -0.25&amp;PLUSMN;1.34 (SD) after 1 yr of GH treatment (P&lt;0.001) and were no longer significantly different from the general population after 4 yr of treatment. There was no correlation between change in Z-score and GH dose or changes in IGF-I and IGF binding protein-3 during treatment. This study demonstrates that 1) improvements in QoL, as measured by the QLS-H, are maintained during long-term GH replacement therapy of adults with GHD, and 2) the QLS-H is a useful tool for evaluating QoL in hypopituitary patients treated in clinical practice. The authors suggest that evaluation of QoL should be a part of the routine clinical management of adult GH-deficient patients, complementing the measurement of surrogate biological markers or other clinical end points.},
  author       = {Rosilio, M and Blum, WF and Edwards, DJ and Shavrikova, EP and Valle, D and Lamberts, SWJ and Erfurth, Eva Marie and Webb, SM and Ross, RJ and Chihara, K and Henrich, G and Herschbach, P and Attanasio, AF},
  issn         = {1945-7197},
  language     = {eng},
  number       = {4},
  pages        = {1684--1693},
  publisher    = {The Endocrine Society},
  series       = {Journal of Clinical Endocrinology and Metabolism},
  title        = {Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H)},
  url          = {http://dx.doi.org/10.1210/jc.2003-030134},
  volume       = {89},
  year         = {2004},
}